The blood cancer multiple myeloma, which involves infection-fighting plasma cells in the bone marrow, affects only about 1% of all cancers -- predominantly individuals over age 65. The disease ...

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained ...

Chimeric antigen receptor T-cell therapy conferred sustained benefit to individuals with high-risk smoldering multiple myeloma, according to phase 2 trial results. All patients who received a single ...

Results of the single-center, phase 2 CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to ...

In order to diagnose a patient with multiple myeloma, a physician will typically order several different tests. That’s because multiple myeloma is a complex disease and knowing the results of these ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Dr Kumar is a ...

Myeloma is a cancer that affects specialised antibody-producing cells called plasma cells. Over your lifetime, your body ...

The team tackled a critical challenge in treating multiple myeloma-a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients. These ...

All 20 smoldering myeloma patients had deep responses after one-time infusion ...

A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in ...

Blood cancers, including leukaemia, lymphoma and multiple myeloma, are among the most quietly progressing cancers in India.